Aristeia Capital’s eFFECTOR Therapeutics, Inc. Warrant EFTRW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-1,303,646
| Closed | -$1.63K | – | 481 |
|
|
2024
Q2 | $1.63K | Sell |
1,303,646
-29,800
| -2% | -$1.03K | ﹤0.01% | 336 |
|
|
2024
Q1 | $183K | Sell |
1,333,446
-159,746
| -11% | -$20.5K | ﹤0.01% | 175 |
|
|
2023
Q4 | $158K | Sell |
1,493,192
-100
| -0% | -$13 | ﹤0.01% | 87 |
|
|
2023
Q3 | $161K | Sell |
1,493,292
-4,403
| -0.3% | -$620 | ﹤0.01% | 92 |
|
|
2023
Q2 | $260K | Sell |
1,497,695
-42,602
| -3% | -$6.82K | 0.01% | 126 |
|
|
2023
Q1 | $153K | Hold |
1,540,297
| – | – | ﹤0.01% | 227 |
|
|
2022
Q4 | $174K | Sell |
1,540,297
-17,177
| -1% | -$2.39K | ﹤0.01% | 331 |
|
|
2022
Q3 | $264K | Sell |
1,557,474
-56,613
| -4% | -$8.85K | ﹤0.01% | 429 |
|
|
2022
Q2 | $379K | Hold |
1,614,087
| – | – | 0.01% | 395 |
|
|
2022
Q1 | $634K | Sell |
1,614,087
-117,859
| -7% | -$59.9K | 0.01% | 391 |
|
|
2021
Q4 | $1.54M | Sell |
1,731,946
-18,054
| -1% | -$22.7K | 0.03% | 389 |
|
|
2021
Q3 | $2.84M | Buy |
1,750,000
+1,466,871
| +518% | +$1.78M | 0.05% | 302 |
|
|
2021
Q2 | $283K | Buy |
+283,129
| New | +$229K | 0.01% | 427 |
|
Aristeia Capital's EFTRW Position: Q3 2024 in Review
Aristeia Capital sold out of eFFECTOR Therapeutics, Inc. Warrant (EFTRW) in Q3 2024, closing a stake of 1,303,646 shares — an estimated $1.63K sold.
Aristeia Capital first reported a position in EFTRW in Q2 2021 and held it in 13 quarters. The position peaked at $2.84M in Q3 2021. 1 fund tracked by Wall St. Rank holds EFTRW as of Q3 2024.
- Aristeia Capital reported no remaining eFFECTOR Therapeutics, Inc. Warrant position as of Q3 2024 after selling out during the quarter.
- Aristeia Capital sold 1,303,646 eFFECTOR Therapeutics, Inc. Warrant shares in Q3 2024, an estimated $1.63K.
- Aristeia Capital first reported a position in eFFECTOR Therapeutics, Inc. Warrant in Q2 2021 and held it in 13 quarters.
- Aristeia Capital's eFFECTOR Therapeutics, Inc. Warrant position peaked at $2.84M in Q3 2021.
- 1 fund tracked by Wall St. Rank held eFFECTOR Therapeutics, Inc. Warrant as of Q3 2024.
Based on Aristeia Capital's 13F filing for Q3 2024, filed 14 Nov 2024.